Mineralocorticoid Receptors Mediate Cardiac Remodelling in Morphine-Dependent Rats

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 2, 2012, Pages 75-80

  Mesripour, Azadeh ^a   Iyer, Abishek ^b   Brown, Lindsay ^b  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CORTICOSTERONE; MALONALDEHYDE; MINERALOCORTICOID RECEPTOR; MORPHINE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; LACRIMATION; MALE; MEAN ARTERIAL PRESSURE; MORPHINE ADDICTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REFLEX; RHINORRHEA; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TREMOR;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HEART VENTRICLES; MALE; MALONDIALDEHYDE; MICROSCOPY, CONFOCAL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MORPHINE; ORGAN SIZE; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; VENTRICULAR REMODELING;

RATTUS;

EID: 84864036777     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00860.x     Document Type: Article

References (27)

1. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3β. Am J Physiol Heart Circ Physiol 2006;291:H827-34.
2. Frässdorf J, Weber NC, Obal D, Toma O, Müllenheim J, Kojda G et al. Morphine induces late cardioprotection in rat hearts in vivo: the involvement of opioid receptors and nuclear transcription factor B. Anesth Analg 2005;101:934-41.
3. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating δ-opioid receptors. Anesthesiology 2008;108:243-50.
4. Habibey R, Pazoki-Toroudi H. Morphine dependence protects rat kidney against ischaemia-reperfusion injury. Clin Exp Pharmacol Physiol 2008;35:1209-14.
5. Kelishomi RH, Ejtemaeemehr S, Tavangar SM, Rahimian R, Mobarakeh JI, Dehpour AR. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology 2008;243:96-104.
6. McNally GP, Carrive P. A telemetric examination of cardiovascular function during the development of, and recovery from, opiate dependence in rats. Physiol Behav 2006;88:55-60.
7. Chan R, Irvine R, White J. Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat. Eur J Pharmacol 1999;368:25-33.
8. Mahinda TB, Lovell BM, Taylor BK. Morphine-induced analgesia, hypotension, and bradycardia are enhanced in hypertensive rats. Anesth Analg 2004;98:1698-704.
9. Mildh LH, Tuomisto LM, Scheinin M, Kirvela O. Morphine-induced cardiovascular stimulation: the effects of two doses on healthy subjects. Anesth Analg 2000;91:51-7.
10. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999;10:S148-53.
11. Eisenberg RM. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists. J Pharmacol Exp Ther 1985;233:863-9.
12. Rabbani M, Hajhashemi V, Mesripour A. Increase in brain corticosterone concentration and recognition memory impairment following morphine withdrawal in mice. Stress 2009;12:451-6.
13. Mesripour A, Hajhashemi V, Rabbani M. The effects of spironolactone on recognition memory loss induced by morphine withdrawal in mice. Res Pharm Sci 2007;2:77-84.
14. Badawy AA, Evans CM, Evans M. Production of tolerance and physical dependence in the rat by simple administration of morphine in drinking water. Br J Pharmacol 1982;75:485-91.
15. Sim AS, Salonikas C, Naidoo D, Wilcken DE. Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J Chromatogr B Biomed Sci Appl 2003;785:337-44.
16. Fenning A, Harrison G, Rose'meyer R, Hoey A, Brown L. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol 2005;289:1408-16.
17. Buccafusco JJ. Cardiovascular changes during morphine withdrawal in the rat: effects of clonidine. Pharmacol Biochem Behav 1983;18:209-15.
18. Evans LE, Swainson CP, Roscoe P, Prescott LF. Treatment of drug overdosage with naloxone, a specific narcotic antagonist. Lancet 1973;1:452-5.
19. Struijker-Boudier HA, Smits JF, De Mey JG. Pharmacology of cardiac and vascular remodeling. Ann Rev Pharmacol Toxicol 1995;35:509-39.
20. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001;38:588-91.
21. Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006;147:S258-68.
22. Lombes M, Farman N, Bonvalet JP, Zennaro MC. Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris) 2000;61:41-6.
23. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-72.
24. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-6.
25. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-7.
26. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-8.
27. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8.